Oct 21 (Reuters) – Fortress Biotech Inc: * FORTRESS BIOTECH AND SUBSIDIARY URICA THERAPEUTICS ANNOUNCE FIRST PATIENTS DOSED IN CRYSTALYS THERAPEUTICS’ GLOBAL PHASE 3 TRIALS OF DOTINURAD FOR THE TREATMENT OF GOUT Source text: Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Nov 12 (Reuters) - JD.com, Inc.: * COMPLETES TAKEOVER OF CECONOMY, BUYS 59.8% FOR EUR…
VIDEO SHOWS: GERMANY TRAIN AT HERZOGENAURACH CAMPUS BEFORE TRAVELLING TO BELGRADE FOR THEIR NATIONS LEAGUE…
By Aditya Soni and Anhata Rooprai Nov 12 (Reuters) - Nvidia CEO Jensen Huang is…
By Aditya Soni and Anhata Rooprai Nov 12 (Reuters) - Nvidia CEO Jensen Huang is…
Nov 12 (Reuters) - Loyal Textile Mills Ltd: * LOYAL TEXTILE MILLS - U THENAPPAN…
VIDEO SHOWS: STILL IMAGES OF PIERRE SAGE/ ARCHIVE FOOTAGE OF THOMAS FRANK/ ARCHIVE FOOTAGE OF…